2025-10-03 - Analysis Report
Okay, here's an analysis of TEM (Unknown Company) based on the provided data, structured with numbers, analysis, and presented in English.

## TEM (Unknown Company) Analysis

**0. Overview**

This report analyzes TEM, an Unknown Company, focusing on its stock performance relative to the S&P 500 (VOO), recent market indicators, news, analyst opinions, earnings, and financial information.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return:**
    *   TEM: 29.57%
    *   VOO: 26.79%
*   **Outperformance:** TEM has outperformed VOO by 2.8%.
*   **Relative Divergence:**
    *   Max: 74.4
    *   Min: -40.6
    *   Current: 2.8
    *   Relative Position: 37.7 (Meaning TEM's current outperformance is at the 37.7th percentile of its historical divergence range with VOO).

**Analysis:** While TEM has outperformed VOO overall, the current outperformance is relatively low compared to its historical range.

*   **Alpha, Beta Analysis (2023-2025):**

| Year       | CAGR  | MDD   | Alpha | Beta | Cap(B) |
|------------|-------|-------|-------|------|--------|
| 2023-2025  | 30.0% | 70.1% | 4.0%  | 0.3  | 13.7   |

**Analysis:** TEM exhibits a significantly lower beta (0.3) compared to the market, indicating lower volatility relative to the S&P 500. With a CAGR of 30.0% and an alpha of 4.0%, TEM demonstrates a capability to generate returns independently of overall market movements. However, the high MDD of 70.1% suggests significant potential for large drawdowns.

**2. Recent Price Action**

*   **Current Price:** 79.34
*   **Last Market Data:** Price = 89.3, Previous Close = 87.99, Change = 1.49
*   **Moving Averages:**
    *   5-day: 79.09
    *   20-day: 82.08
    *   60-day: 70.32

**Analysis:** The price is below its 20-day moving average but above its 5-day and 60-day averages.  The last market data shows a price of 89.3, with a change of 1.49. This suggests that the current price of 79.34 may be outdated and does not reflect recent market activity. There is an upward price trend according to last market data.

**3. Market Risk Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 47.57 (Neutral)
*   **PPO:** -1.84 (Negative, suggests potential downward momentum)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (13 shares - Very Safe - MRI:0.90) Monthly invest 5.9% of total investment ($1,000.00)
*   **Recent (20-day) Relative Divergence Change:** -8.5 (Negative, indicates short-term decline relative to VOO)
*   **Expected Return:** NaN

**Analysis:**  The MRI suggests a high investment recommendation, but the negative PPO and declining relative divergence indicate potential short-term weakness. The RSI is neutral. The "Hybrid Signal" recommends full investment, suggesting confidence despite the short-term indicators. The NaN expected return indicates no data available for long-term outperformance projections.

**4. Recent News & Significant Events**

*   **Recent News Highlights:**
    *   FDA Clearance for Tempus xR IVD (RNA NGS In Vitro Diagnostic Device) - *Positive*
    *   Analyst focus on valuation in the absence of clear catalysts.
    *   Comparison with ILMN in precision oncology.
    *   Pullback from record high after FDA clearance.
    *   Coverage in IBD 50.

**Analysis:** The news is mixed. The FDA clearance is a positive catalyst, potentially driving growth. However, concerns about valuation and a recent pullback suggest some caution.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (2.15)
*   **Number of Opinions:** 11
*   **Target Price:**
    *   Average: 77.55
    *   High: 100.00
    *   Low: 60.00

**Analysis:**  Analysts generally have a "Buy" rating with a wide range of target prices. The average target price (77.55) is below the recent price (89.3), suggesting potential overvaluation based on consensus.

**5. Recent Earnings Analysis**

| Date       | EPS   | Expected EPS |
|------------|-------|--------------|
| 2025-08-08 | -0.22 | -0.22988     |
| 2025-05-06 | -0.24 | -0.26003     |
| 2025-02-24 | -0.18 | -0.15        |
| 2024-11-04 | -0.25 | -0.26608     |
| 2024-08-06 | -0.63 | -0.59        |

**Analysis:** The company has consistently reported negative EPS, but has often beaten expectations. This could indicate improving efficiency or cost management.

**6. Financial Information**

*   **Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.31B  | 61.99%        |
| 2025-03-31 | $0.26B  | 60.69%        |
| 2024-12-31 | $0.20B  | 60.83%        |
| 2024-09-30 | $0.18B  | 58.50%        |
| 2024-06-30 | $0.17B  | 45.50%        |

*   **Capital and Profitability:**

| Quarter    | Equity  | ROE       |
|------------|---------|-----------|
| 2025-06-30 | $0.31B  | -13.84%   |
| 2025-03-31 | $0.33B  | -20.86%   |
| 2024-12-31 | $0.06B  | -23.10%   |
| 2024-09-30 | $0.05B  | -141.16%  |
| 2024-06-30 | $0.10B  | -562.04%  |

**Analysis:**  Revenue is growing consistently quarter-over-quarter, and profit margins are high and improving. However, the company exhibits negative Return on Equity (ROE), indicating low profitability relative to shareholders' equity. The ROE values have been negative, indicating losses relative to equity.

**7. Summary**

TEM is a company in the precision oncology space with recent FDA clearance potentially driving growth. However, there are some key points to consider:

*   **Positive:**
    *   Outperforming S&P 500 over the covered period.
    *   High and improving profit margins.
    *   Revenue growth.
    *   Recent FDA clearance.
    *   Strong analyst consensus (Buy).
*   **Neutral:**
    *   Neutral RSI
    *   Hybrid signal indicates a "Buy" recommendation
*   **Negative:**
    *   The recent relative divergence with VOO has been declining.
    *   Negative EPS and ROE.
    *   Analysts have raised concerns about valuation.
    *   The price is trading around its 20-day moving average
    *   The High MDD of 70.1%

**Overall:** TEM presents a mixed picture. The positive news and revenue growth are encouraging. However, the negative EPS, ROE, and valuation concerns warrant careful consideration. Further research into the company's long-term profitability and growth strategy is recommended.
